Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at ...
CARDIOTTRansform missed its primary endpoint, but its secondary analysis of eplontersen in ATTR-CM patients on background ...
FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS ...
Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its ...
Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf ...
Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for ...
How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing ...
Akeso's ivonescimab met overall survival endpoint in Phase III trial for EGFR-TKI-resistant NSCLC, with consistent results ...
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial data.
MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal ...
Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in ...
On June 22, 2026, the FDA sent a warning letter, reference CBER 26-728681, to Genzyme Ireland Limited in Waterford, following an inspection conducted between January 12 and January 20 of that year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results